Rheumatology 1999; 38: 1282-1284
© 1999 British Society for Rheumatology
Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line therapy
Department of Clinical and Experimental Medicine, Section of Internal Medicine and Oncological Sciences, Centre for the Study of Rheumatic Diseases, University of Perugia,
1 Department of Clinical and Experimental Medicine, Section of Internal Medicine, University of Verona,
2 Institute of Internal Medicine, University of L'Aquila, Italy and
3 Department of Rheumatology, Division of Medicine, Guy's, King's and St Thomas' School of Medicine (GKT), Guy's Campus, London, UK
Correspondence to:
R. Gerli, Dipartimento di Medicina Clinica e Sperimentale, Sez di Medicina Interna e Scienze Oncologiche, Centro per lo Studio delle Malattie Reumatiche, Policlinico di Monteluce, I-06122 Perugia, Italy.
Objective. To evaluate whether serum levels of the soluble form of CD30 (sCD30) correlate with disease activity in early rheumatoid arthritis (RA) and may have prognostic value in predicting the response to disease-modifying anti-rheumatic drugs (DMARDs).
Methods. The levels of sCD30 and C-reactive protein (CRP) were measured in the serum of 14 untreated subjects with early RA, before and during treatment with hydroxychloroquine, for a follow-up period of 8 months. At the end of the study, patients were also evaluated for their response to DMARDs.
Results. An inverse correlation between sCD30 and CRP serum values was demonstrated at baseline, but not during the follow-up. Patients who responded to DMARD therapy had higher sCD30 basal levels than non-responders.
Conclusions. The evaluation of sCD30 serum levels in early RA may reflect the attempt by CD30+ T cells to downmodulate inflammation and may be a useful marker to predict a good response to DMARDs.
KEY WORDS: CD30, sCD30, Rheumatoid arthritis, T lymphocytes, C-reactive protein, Disease-modifying anti-rheumatic drugs
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Gerli, C. Lunardi, and C. Pitzalis Unmasking the anti-inflammatory cytokine response in rheumatoid synovitis Rheumatology, December 1, 2002; 41(12): 1341 - 1345. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Susal, S. Pelzl, B. Dohler, and G. Opelz Identification of Highly Responsive Kidney Transplant Recipients Using Pretransplant Soluble CD30 J. Am. Soc. Nephrol., June 1, 2002; 13(6): 1650 - 1656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gerli, C. Pitzalis, O. Bistoni, B. Falini, V. Costantini, A. Russano, and C. Lunardi CD30+ T Cells in Rheumatoid Synovitis: Mechanisms of Recruitment and Functional Role J. Immunol., April 15, 2000; 164(8): 4399 - 4407. [Abstract] [Full Text] [PDF]
|
|